Ken Griffin Bridge Bio Pharma, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 231,500 shares of BBIO stock, worth $6.16 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
231,500
Previous 313,000
26.04%
Holding current value
$6.16 Million
Previous $7.93 Million
25.67%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding BBIO
# of Institutions
291Shares Held
171MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$672 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$668 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$378 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$331 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$161 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.94B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...